From: Vaccine Insights Tuck Seng Wong, Kiat Ruxrungtham Vaccine security and self-reliance must be a priority for all nations if they are to escape the worst h
The mRNA Technology Transfer Programme organized on 18 March 2024 in Singapore the 4th Sc
From https://www.who.int/news-room/events/detail/2023/10/31/default-calendar/who-mpp-regional-mrna-meeting-in-searo-wpro WHO/MPP mRNA Technology Transfer Progr
From: Department of Chemical and Biological Engineering, University of Sheffield Professor Tuck Seng Wong Sheffield to lead £7.6 million UK-South East Asia Vac
Congratulations to Drew Weissman and Katalin Kariko for the Nobel Prize in Physiology or Medicine 2023. You have accomplished such a great contribution to the
From: The Independent Panel for Pandemic Preparedness and Response Statement of the Right Honourable Helen Clark Former Co-ChairThe Independent Panel for
From BioNet-Asia ChulaCov19 BNA159 is a COVID–19 mRNA vaccine developed by Chulalongkorn University and produced by BioNet ChulaCov19 mRNA vaccine was fou
เปิดรับสมัครอาสาสมัครสุขภาพดีสำหรับโครงการ ChulaCov19 BNA159 mRNA vaccine คุณสมบัติ อายุ 18 – 60 ปีไม่มีโรคประจำตัวไม่เคยติดเชื้อ covid19ไม่เคยได้รับวัคซีน cov
A COVID-19 vaccine made by BioNet-Asia in Ayutthaya, Thailand, should be cheaper than the two messenger RNA vaccines used in richer countries.ADAM DEAN From: S
Dr.Chanchai Sittipunt, Dr.Nakorn Premsri, Dr.Suthipong Watcharasin and Dr.Kiat Ruxrungtham greetings to three Prince Mahidol Award 2021 laureates
Amid a global shortage of vaccines and a new wave of COVID-19 infections, some countries in Southeast Asia are rushing to develop their own coronavirus shots.
COVID19 Vaccine Tracker – Chulalongkorn University: ChulaCov19
The research team behind the development of a local mRNA Covid-19 vaccine on Monday asked the government to help finance the project
The mRNA vaccine, currently being developed by the Vaccine Research Centre of the Faculty of Medicine of Chulalongkorn University, can stimulate the immune system to produce killer T-cells
The Phase 1 trial of Thailand’s homegrown mRNA COVID-19 vaccine ChulaCOV-19, suggests the candidate vaccine can help the body elicit
The Faculty of Medicine at Bangkok’s Chulalongkorn University has put out a call for healthy volunteers to take part in trials of its Covid-19 mRNA vaccine.
TriLink enables Chula VRC to take its Covid-19 vaccine into a First in Human (FIH) phase 1 clinical trial in Thailand with mRNA
